Please Wait
Applying Filters...
menu
    • menu
    Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Jan 2025: J&J’s US$ 14.6 bn Intra-Cellular buyout kicks off deal frenzy; Ozempic clinches FDA nod for CKD

    Stock Recap
    #PipelineProspector

    Menu

    DDAVP

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 286,501Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    24/02/2025 Aspen API
    Netherlands
    		 ASPEN OSS B.V. Oss NL R1-CEP 1999-165 - Rev 05 Desmopressin 2016-03-31 Valid Chemical 712
    24/02/2025 Bachem AG
    Switzerland
    		 BACHEM AMERICAS, INC. Torrance US R1-CEP 2007-157 - Rev 02 Desmopressin 2023-06-29 Valid Chemical 712